Acute Ischemic Stroke Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Acute Ischemic Stroke is characterized
by the impact of an obstruction within a blood vessel supplying blood to the
brain. Stroke is one of the leading causes of death and disability worldwide.
The blockage of blood flow to the brain inevitably causes acute ischemic
stroke. Once the tissue oxygenation starts, depending on the time elapsed, the
patient's situation changes—the lesser the time, the better the prognosis. At
the cellular level, the sudden interruption or blockage of blood flow to the
brain due to a blood clot (thrombus) or a plaque (fatty deposits) deprives the
brain tissue of the necessary nutrients and oxygen, which leads to irreversible
brain tissue damage. Ischemic stroke causes mitochondrial cell death. For AIS
treatment, tPA is the gold standard and associated with improved clinical
patient outcomes. The sooner the IV tPA is administered after the onset of
stroke symptoms, the better the outcome.
- Blood-brain barrier (BBB) disruption in acute ischemic stroke
varies considerably from 15% to 66 %
- The crude annual incidence rate of 119.84 per 100,000 cases
of acute ischemic stroke with a male to female ratio of 1.2:1, with 64% of
patients included in the 65 to 84 age groups.
Thelansis’s “Acute Ischemic Stroke Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Acute
Ischemic Stroke treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Acute Ischemic Stroke across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Acute Ischemic Stroke Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment